Rocket One Inc(HOTH) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -0.81 | Insider Own | 2.89% | Shs Outstand | 19.1M | Perf Week | 126.67% |
| Market Cap | 0.03B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 18.6M | Perf Month | 74.36% |
| Enterprise Value | 0.02B | PEG | - | EPS next Q | - | Inst Own | 4.11% | Short Float | 4.29% | Perf Quarter | 28.3% |
| Income | -0.01B | P/S | - | EPS this Y | - | Inst Trans | -1.73% | Short Ratio | 0.29 | Perf Half Y | 25.35% |
| Sales | 0.00B | P/B | 5.32 | EPS next 5Y | - | ROA | -130.21% | Short Interest | 0.80M | Perf YTD | 37.37% |
| Book/sh | 0.26 | P/C | 6.42 | EPS past 3/5Y | 54.35% 42.65% | ROE | -148.85% | 52W High | -35.7% ($2.12) | Perf Year | 58.21% |
| Cash/sh | 0.21 | P/FCF | - | Sales past 3/5Y | - | ROIC | -280.82% | 52W Low | 177.89% ($0.49) | Perf 3Y | -14.47% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 29.47% | Gross Margin | - | Volatility(W/M) | 8.75% 6.78% | Perf 5Y | -96.24% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.11 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 3.35 | EPS Q/Q | 37.57% | Profit Margin | - | RSI (14) | 84.54 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 3.35 | Sales Q/Q | - | SMA20 | 91.54% ($0.71) | Beta | 0.57 | Target Price | $5 |
| Payout | - | Debt/Eq | 0 | Earnings | 2026/02/25 | SMA50 | 85.54% ($0.73) | Rel Volume | 50.97 | Prev Close | $0.71 |
| Employees | 6 | LT Debt/Eq | 0 | EPS/Sales Surpr. | 0.73% - | SMA200 | 22.62% ($1.11) | Avg Volume(3M) | 2.76M | Price | $1.36 |
| IPO | 2019/2/15 | Option/Short | No/Yes | Trades | 154600 | Volume | 140,874,056 | Change | 92.01% |
Hoth Therapeutics is a U.S. clinical-stage small-cap biotech with a diverse pipeline focused on dermatological conditions and oncology supportive care. Its lead candidate is HT-001, a topical gel formulation designed to alleviate skin side effects in patients treated with EGFR anti-cancer drugs, and the company is expanding indications with BioLexa, targeting atopic dermatitis, and HT-KIT for a rare disease, among others.
Over the past 1 year, roughly in the middle
36% below its 1-year high.
Traded more than usual. That is 5097% of its average volume.
HOTH has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -96.2%. The S&P 500 did +64% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 4.1%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
VTI Vanguard Morningstar Total Stock Market ETF <0.01% 
VXF Vanguard Extended Market Index ETF <0.01% It ranks #459 of 598 in the industry
Based on market cap of $26M.
ABVC#455 ABVC BioPharma Inc $26M PER - 
BYSI#456 BeyondSpring Inc $26M PER - 
IMMP#457 Immutep Limited ADR $26M PER - 
PLRZ#458 Polyrizon Ltd $26M PER - HOTH#459 Rocket One Inc $26M PER - 
FAQ
What kind of company is HOTH?
HOTH belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of HOTH?
The market cap of HOTH is approximately $26M, ranking 5,205 within its sector.
What is the 52-week high and low for HOTH?
HOTH has recorded a 52-week high of $2.12 and a low of $0.49.
